Pfizer licensed Cartography Biosciences’ ATLAS and SUMMIT platforms to discover tumor‑selective antigens and antigen pairs for an undisclosed cancer indication. Cartography is eligible for up to $65 million in upfront, near‑term and option payments and more than $850 million in combined development and commercial milestones if multiple options are exercised. Cartography will use its single‑cell RNA and computational tools to nominate targets; Pfizer will handle downstream research, development and commercialization. The collaboration underscores pharma demand for single‑cell and computational target discovery tools to improve precision of T‑cell engagers and multispecific therapies.